Eli Lilly's Mounjaro has become the world's best-selling drug after surpassing the cancer medication Keytruda in the first quarter of 2026 [1].
This shift reflects a broader change in the global pharmaceutical market, where medications targeting metabolic health and obesity are now competing with high-cost oncology treatments for financial dominance.
According to Bloomberg data, Mounjaro generated U.S. $8.7 billion [1] in sales during the first quarter of 2026. This figure exceeds the revenue recorded by Merck's Keytruda, which brought in U.S. $7.9 billion [1] during the same period.
Keytruda has long held a position as a top revenue generator due to its wide application in treating various types of cancer. However, the rapid adoption of Mounjaro, used for diabetes and obesity, has altered the ranking of the most profitable medications globally [1].
The growth of the GLP-1 receptor agonist market has created a new tier of "blockbuster" drugs. These medications are seeing unprecedented demand as healthcare providers expand their use for weight management, and related metabolic conditions [1].
Eli Lilly and Merck continue to dominate different sectors of the medical industry, but the current sales figures highlight the massive commercial scale of obesity treatments. The gap between the two drugs in the first quarter was approximately U.S. $800 million [1].
“Mounjaro generated US$ 8.7 billion in sales during the first quarter of 2026.”
The ascent of Mounjaro to the top spot indicates that the market for obesity and diabetes medications is now larger than that of specialized oncology treatments. This transition suggests a pivot in pharmaceutical investment and priority toward chronic metabolic conditions, which affect a larger portion of the global population than specific cancer types.
